Exchange: NASDAQ·Updated 04:15 PM EDT

About CUE

About

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in advancing a portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its pipeline includes CUE-221, a novel anti-IgE antibody with a dual mechanism of action, and CUE-401, designed to regulate inflammation and drive Treg-mediated tolerance. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
29

Frequently Asked Questions

What is Market Cap of Cue Biopharma Inc?
What is the 52-week high for Cue Biopharma Inc?
What is the 52-week low for Cue Biopharma Inc?
What is Cue Biopharma Inc stock price today?
What was Cue Biopharma Inc stock price yesterday?
What is the PE ratio of Cue Biopharma Inc?
What is the Price-to-Book ratio of Cue Biopharma Inc?
What is the 50-day moving average of Cue Biopharma Inc?
How many employees does Cue Biopharma Inc have?

Advertisement|Remove ads.